Copyright
©The Author(s) 2020.
World J Gastrointest Oncol. Apr 15, 2020; 12(4): 467-482
Published online Apr 15, 2020. doi: 10.4251/wjgo.v12.i4.467
Published online Apr 15, 2020. doi: 10.4251/wjgo.v12.i4.467
Table 1 Baseline characteristics of included patients
Variables | All patients (n = 530) | Derivation cohort (n = 265) | Validation cohort (n = 265) | P value |
Patient factors/laboratory parameters | ||||
Age, yr | 57.2 (10.7) | 57.9 (10.5) | 56.5 (10.8) | 0.131 |
Male gender, n (%) | 256 (48.3) | 134 (50.6) | 122 (46.0) | 0.339 |
HBsAg (positive), n (%) | 153 (29.0) | 80 (30.3) | 73 (27.7) | 0.565 |
Hepatolithiasis, n (%) | 89 (16.8) | 42 (15.6) | 47 (17.9) | 0.487 |
CA-199 < 22, n (%) | 150 (29.0) | 77 (30.0) | 73 (28.0) | 0.738 |
Platelet | 178 (72) | 179 (73) | 177 (71) | 0.778 |
Neutrophil | 4.6 (2.1) | 4.6 (2.3) | 4.6 (2.0) | 0.976 |
Lymphocyte | 1.6 (0.9) | 1.6 (1.2) | 1.6 (0.5) | 0.641 |
NLR | 3.38 (2.95) | 3.34 (2.22) | 3.42 (3.54) | 0.746 |
PLR | 126 (68) | 127 (65) | 125 (70) | 0.716 |
SII | 612 (635) | 605 (495) | 619 (751) | 0.803 |
Histological and gross features of tumors | ||||
Tumor size, cm | 6.0 (2.7) | 6.0 (2.7) | 6.0 (2.7) | 0.783 |
Solitary tumor, n (%) | 373 (70.4) | 196 (74.0) | 177 (66.8) | 0.087 |
Well tumor differentiation, n (%) | 22 (4.2) | 11 (4.2) | 11 (4.2) | 1.000 |
Macrovascular invasion, n (%) | 123 (23.2) | 71 (26.8) | 52 (19.6) | 0.064 |
Microvascular invasion, n (%) | 54 (10.2) | 27 (10.2) | 27 (10.2) | 1.000 |
Node positive, n (%) | 129 (24.3) | 61 (23.0) | 68 (25.7) | 0.544 |
Perineural invasion, n (%) | 80 (15.1) | 38 (14.3) | 42 (15.8) | 0.716 |
TNM stage, n (%) | 0.902 | |||
IA | 63 (11.9) | 33 (12.5) | 30 (11.3) | |
IB | 38 (7.2) | 21 (7.9) | 17 (6.4) | |
II | 56 (10.6) | 26 (9.8) | 30 (11.3) | |
IIIA | 242 (45.7) | 122 (46.0) | 120 (45.3) | |
IIIB | 131 (24.7) | 63 (23.8) | 68 (25.7) | |
Follow-up, median (range) | 18.0 (1.0-115.4) | 18.2 (1.0-115.4) | 17.8 (1.2-104.5) |
Table 2 Correlation between systemic immune-inflammation index and clinicopathological characteristics in derivation and validation cohort
Variables | Derivation | Validation | ||||
SII ≤ 450 | SII > 450 | P value | SII ≤ 450 | SII > 450 | P value | |
Total patients | 123 | 142 | 130 | 135 | ||
Age, yr | 57.89 (9.5) | 57.98 (11.3) | 0.943 | 57.79 (10.7) | 55.41 (10.9) | 0.074 |
Male gender, n (%) | 67 (54.5) | 67 (47.2) | 0.268 | 61 (46.9) | 61 (45.2) | 0.806 |
HBsAg, n (%) | 45 (36.9) | 35 (24.6) | 0.033 | 39 (30.2) | 34 (25.2) | 0.413 |
Hepatolithiasis, n (%) | 15 (12.2) | 27 (19.0) | 0.164 | 22 (16.9) | 25 (18.5) | 0.758 |
CA-199 < 22, n (%) | 40 (33.1) | 37 (27.2) | 0.010 | 45 (34.9) | 28 (21.2) | 0.002 |
Platelet | 139 (45) | 214 (75) | < 0.001 | 141 (50) | 213 (70) | < 0.001 |
Neutrophil | 3.34 (1.0) | 5.65 (2.5) | < 0.001 | 3.46 (1.3) | 5.66 (1.9) | < 0.001 |
Lymphocyte | 1.81 (1.7) | 1.43 (0.5) | 0.009 | 1.73 (0.5) | 1.41 (0.5) | < 0.001 |
Tumor size, cm | 5.2 (2.3) | 6.5 (2.9) | < 0.001 | 5.40 (2.2) | 6.36 (3.0) | 0.007 |
Solitary tumor, n (%) | 99 (80.5) | 97 (68.3) | 0.025 | 92 (70.8) | 86 (63.0) | 0.197 |
Well tumor differentiation, n (%) | 7 (5.7) | 4 (2.8) | 0.357 | 8 (6.2) | 3 (2.2) | 0.110 |
Macrovascular invasion, n (%) | 33 (26.8) | 38 (26.8) | 1.000 | 23 (17.7) | 29 (21.5) | 0.449 |
Microvascular invasion, n (%) | 12 (9.8) | 15 (10.6) | 0.844 | 9 (6.9) | 18 (13.3) | 0.103 |
Node positive, n (%) | 20 (16.3) | 41 (28.9) | 0.020 | 27 (20.8) | 41 (30.4) | 0.089 |
Perineural invasion, n (%) | 19 (15.4) | 19 (13.4) | 0.732 | 22 (16.9) | 20 (14.8) | 0.745 |
TNM stage, n (%) | 0.017 | 0.123 | ||||
IA | 22 (17.9) | 11 (7.7) | 16 (12.3) | 14 (10.4) | ||
IB | 11 (8.9) | 10 (7.0) | 8 (6.2) | 9 (6.7) | ||
II | 14 (11.4) | 12 (8.5) | 11 (8.5) | 19 (14.1) | ||
IIIA | 56 (45.5) | 66 (46.5) | 68 (52.3) | 52 (38.5) | ||
IIIB | 20 (16.3) | 43 (30.3) | 27 (20.8) | 41 (30.4) |
Table 3 Univariate analysis in the derivation cohort
Variables | Overall survival | Recurrence-free survival | ||||
HR | 95%CI | P value | HR | 95%CI | P value | |
Age, yr (> 60/≤ 60) | 0.917 | 0.669-1.258 | 0.592 | 0.998 | 0.749-1.330 | 0.991 |
Gender (F/M) | 0.747 | 0.546-1.023 | 0.069 | 0.791 | 0.594-1.052 | 0.107 |
HBsAg | 1.347 | 0.966-1.878 | 0.079 | 1.289 | 0.947-1.753 | 0.106 |
Hepatolithiasis | 1.775 | 1.179-2.675 | 0.006 | 1.357 | 0.913-2.018 | 0.131 |
CA-199 (≥ 22/< 22) | 1.631 | 1.122-2.370 | 0.010 | 1.357 | 0.981-1.876 | 0.065 |
Tumor size (≥ 5/< 5) | 1.171 | 0.853-1.608 | 0.328 | 1.359 | 1.016-1.818 | 0.039 |
Tumor number (multiple/single) | 1.686 | 1.204-2.362 | 0.002 | 1.953 | 1.436-2.658 | < 0.001 |
Tumor differentiation (moderate-poor/well) | 5.326 | 1.318-21.519 | 0.019 | 4.498 | 1.434-14.110 | 0.010 |
Macrovascular invasion | 1.076 | 0.753-1.538 | 0.688 | 1.014 | 0.756-1.453 | 0.776 |
Microvascular invasion | 1.683 | 1.062-2.667 | 0.027 | 2.022 | 1.325-3.088 | 0.001 |
Node positive | 2.696 | 1.928-3.769 | < 0.001 | 1.955 | 1.424-2.684 | < 0.001 |
Perineural invasion | 1.174 | 0.832-1.656 | 0.360 | 1.443 | 0.976-2.134 | 0.066 |
TNM stage (III/I-II) | 1.663 | 1.090-2.539 | 0.018 | 1.529 | 1.130-2.068 | 0.006 |
NLR (> 2.65/≤ 2.65) | 1.609 | 1.171-2.212 | 0.003 | 1.482 | 1.111-1.978 | 0.007 |
PLR (> 110/≤ 110) | 1.482 | 1.069-2.055 | 0.018 | 1.325 | 0.989-1.776 | 0.060 |
SII (> 450/≤ 450) | 1.774 | 1.285-2.449 | < 0.001 | 1.455 | 1.088-1.946 | 0.011 |
Table 4 Multivariate analysis in the derivation cohort
Variables | Overall survival | Recurrence-free survival | ||||
HR | 95%CI | P value | HR | 95%CI | P value | |
Hepatolithiasis | 1.348 | 0.870-2.088 | 0.182 | |||
CA-199 (≥ 22/< 22) | 1.458 | 0.979-2.170 | 0.064 | |||
Tumor size (≥ 5/<5) | 0.873 | 0.556-1.371 | 0.555 | |||
Tumor number (multiple/single) | 1.666 | 1.140-2.434 | 0.008 | 1.679 | 1.200-2.348 | 0.002 |
Tumor differentiation (moderate-poor/well) | 3.061 | 0.739-12.675 | 0.123 | 2.813 | 0.877-9.022 | 0.082 |
Microvascular invasion | 0.938 | 0.556-1.582 | 0.809 | |||
Node positive | 2.377 | 1.586-3.562 | < 0.001 | 1.881 | 1.316-2.688 | 0.001 |
TNM stage (III/I-II) | 0.682 | 0.456-1.022 | 0.064 | 0.756 | 0.527-1.085 | 0.129 |
SII (> 450/≤ 450) | 1.774 | 1.245-2.528 | 0.002 | 1.385 | 1.005-1.909 | 0.046 |
- Citation: Li H, Wang JJ, Zhang M, Ren B, Li JX, Xu L, Wu H. Prognostic significance of systemic immune-inflammation index in patients with intrahepatic cholangiocarcinoma undergoing hepatic resection. World J Gastrointest Oncol 2020; 12(4): 467-482
- URL: https://www.wjgnet.com/1948-5204/full/v12/i4/467.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v12.i4.467